Many people approach the holidays expecting to feel merry and bright, but that isn’t always realistic. You may be struggling ...
Why hadn’t I been able to save my son? What biological mechanisms made him so relentlessly ill? Could more effective ...
Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in ...
Mount Sinai receives $4.5 million grant to investigate neural mechanisms underlying bipolar disorder
The Icahn School of Medicine at Mount Sinai is pleased to announce it has received a three-year, $4.5 million grant from BD2: ...
Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company (BMY) ...
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...
HALIFAX, Nova Scotia, CANADA, 7 October 2025 -- In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr. Martin Alda illuminates how decoding psychiatric heterogeneity holds ...
Were you Seen at The Harvest Moon Fall for a Cure Gala to Benefit the Arthritis Foundation on Oct. 3, 2025, at Brown's Revolution Hall in Troy? The event honored Kendra Zappia, DDS, with the 2025 ...
This week, the Trump administration announced that the FDA had approved leucovorin, a generic drug, as a treatment for autism. The announcement shocked health experts because the FDA’s usual approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback